Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Identifying Relations Between Imaging Phenotypes And Molecular Subtypes Of Breast Cancer: Model Discovery And External Validation

J. Wu, Xiaoli Sun, J. Wang, Y. Cui, F. Kato, H. Shirato, D. Ikeda, R. Li
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
To determine whether dynamic contrast enhancement magnetic resonance imaging (DCE‐MRI) characteristics of the breast tumor and background parenchyma can distinguish molecular subtypes (ie, luminal A/B or basal) of breast cancer.
This paper references
10.1148/radiol.15142698
Breast Cancer: Radiogenomic Biomarker Reveals Associations among Dynamic Contrast-enhanced MR Imaging, Long Noncoding RNA, and Metastasis.
S. Yamamoto (2015)
10.1007/s00330-015-3845-6
Magnetic resonance imaging texture analysis classification of primary breast cancer
S. Waugh (2015)
molecular classes predicts response to neoadjuvant chemotherapy
J Baselga (2010)
10.2214/AJR.11.7824
Radiogenomic analysis of breast cancer using MRI: a preliminary study to define the landscape.
S. Yamamoto (2012)
10.1007/s00330-012-2403-8
Correlations between diffusion-weighted imaging and breast cancer biomarkers
L. Martincich (2012)
10.1109/TMI.2010.2046908
N4ITK: Improved N3 Bias Correction
N. Tustison (2010)
10.1038/35021093
Molecular portraits of human breast tumours
C. Perou (2000)
10.1007/s00330-015-4011-x
Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response
H. Preibsch (2015)
10.1097/MD.0000000000003000
Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging
Ji Soo Choi (2016)
10.1200/JCO.2013.54.1870
Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.
F. Ades (2014)
10.2214/AJR.07.2533
Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy.
J. Hattangadi (2008)
10.1038/modpathol.2010.33
Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy
S. Schnitt (2010)
10.1148/radiol.2015150013
Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
N. Hylton (2016)
10.1148/radiol.15142192
Association between Parenchymal Enhancement of the Contralateral Breast in Dynamic Contrast-enhanced MR Imaging and Outcome of Patients with Unilateral Invasive Breast Cancer.
Bas H. M. van der Velden (2015)
10.1111/J.2517-6161.1996.TB02080.X
Regression Shrinkage and Selection via the Lasso
R. Tibshirani (1996)
10.1002/jmri.25119
Breast cancer molecular subtype classifier that incorporates MRI features
E. Sutton (2016)
10.1016/J.YONC.2012.08.009
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
J. Thigpen (2012)
10.1002/jmri.24884
MRI phenotype of breast cancer: Kinetic assessment for molecular subtypes
Eric M Blaschke (2015)
10.1158/1078-0432.CCR-16-2415
Unsupervised Clustering of Quantitative Image Phenotypes Reveals Breast Cancer Subtypes with Distinct Prognoses and Molecular Pathways
J. Wu (2017)
10.1093/annonc/mdr304
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch (2011)
10.1148/radiol.11102156
Background parenchymal enhancement at breast MR imaging and breast cancer risk.
Valencia King (2011)
10.1148/RADIOL.2016152110
MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.
H. Li (2016)
10.1073/pnas.1732912100
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
C. Sotiriou (2003)
10.1093/annonc/mds586
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.
S. Guiu (2012)
10.1148/radiol.13130459
Background parenchymal signal enhancement ratio at preoperative MR imaging: association with subsequent local recurrence in patients with ductal carcinoma in situ after breast conservation surgery.
Sun-Ah Kim (2014)
10.1200/JCO.2008.18.1370
Supervised risk predictor of breast cancer based on intrinsic subtypes.
J. Parker (2009)
10.1148/radiol.2015151169
Radiomics: Images Are More than Pictures, They Are Data
R. Gillies (2016)
10.1016/J.BREASTDIS.2015.10.008
Identification of Intrinsic Imaging Phenotypes for Breast Cancer Tumors: Preliminary Associations with Gene Expression Profiles
K. Shin (2015)
10.1002/jmri.24934
Histogram analysis of apparent diffusion coefficient at 3.0t: Correlation with prognostic factors and subtypes of invasive ductal carcinoma
Eun Jeong Kim (2015)
10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
Index for rating diagnostic tests
W. Youden (1950)
10.1148/radiol.14132641
Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging.
M. Mazurowski (2014)
10.1148/radiol.2015142304
Are Qualitative Assessments of Background Parenchymal Enhancement, Amount of Fibroglandular Tissue on MR Images, and Mammographic Density Associated with Breast Cancer Risk?
Brian N Dontchos (2015)
10.1371/journal.pone.0143308
Identifying Triple-Negative Breast Cancer Using Background Parenchymal Enhancement Heterogeneity on Dynamic Contrast-Enhanced MRI: A Pilot Radiomics Study
J. Wang (2015)
10.1002/jmri.25279
Intratumor partitioning and texture analysis of dynamic contrast‐enhanced (DCE)‐MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy
J. Wu (2016)
10.1148/radiol.14121031
Computerized image analysis for identifying triple-negative breast cancers and differentiating them from other molecular subtypes of breast cancer on dynamic contrast-enhanced MR images: a feasibility study.
S. Agner (2014)
10.1016/j.mric.2013.02.005
Updates and revisions to the BI-RADS magnetic resonance imaging lexicon.
Sonya D Edwards (2013)
10.1002/CNCR.25798
Erratum: Immunohistochemical Surrogate Markers of Breast Cancer Molecular Classes Predicts Response to Neoadjuvant Chemotherapy
R. Bhargava (2011)
10.1200/JCO.2006.07.1522
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
S. Loi (2007)
10.1148/radiol.12110748
Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
N. Hylton (2012)
10.1080/07357900701784238
Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer
J. Peppercorn (2008)
Index for rating diagnostic tests. Cancer 1950;3:32–35
WJ Youden (1950)
10.1002/jmri.24890
Breast cancer subtype intertumor heterogeneity: MRI‐based features predict results of a genomic assay
E. Sutton (2015)



This paper is referenced by
10.1007/s11307-019-01383-w
Radiomic Signatures Derived from Diffusion-Weighted Imaging for the Assessment of Breast Cancer Receptor Status and Molecular Subtypes
D. Leithner (2019)
10.1007/978-3-319-94878-2
Artificial Intelligence in Medical Imaging
E. Ranschaert (2019)
10.1007/s11517-017-1770-3
Automated breast tumor detection and segmentation with a novel computational framework of whole ultrasound images
L. Liu (2017)
10.1016/j.acra.2018.01.023
Breast Cancer Molecular Subtype Prediction by Mammographic Radiomic Features.
W. Ma (2019)
10.1007/s00330-019-06084-0
Can peritumoral radiomics increase the efficiency of the prediction for lymph node metastasis in clinical stage T1 lung adenocarcinoma on CT?
X. Wang (2019)
10.1038/s41416-018-0185-8
A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features
Ashirbani Saha (2018)
10.1186/s13244-020-00895-2
Integrative radiogenomics for virtual biopsy and treatment monitoring in ovarian cancer
Paula Martín-González (2020)
10.1002/jmri.26762
Background parenchymal enhancement on breast MRI: A comprehensive review
G. Liao (2019)
10.3389/fonc.2019.01062
Predictive Power of a Radiomic Signature Based on 18F-FDG PET/CT Images for EGFR Mutational Status in NSCLC
X. Li (2019)
10.1148/radiol.2017162823
Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer.
J. Wu (2017)
10.1016/j.jconrel.2017.10.036
Targeted cancer therapy through antibody fragments‐decorated nanomedicines
A. Alibakhshi (2017)
10.1002/mp.12925
Breast cancer MRI radiomics: An overview of algorithmic features and impact of inter‐reader variability in annotating tumors
Ashirbani Saha (2018)
10.1001/jamanetworkopen.2019.2561
Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)–Positive Breast Cancer
Nathaniel Braman (2019)
10.1007/s00330-018-5891-3
Radiomic analysis of imaging heterogeneity in tumours and the surrounding parenchyma based on unsupervised decomposition of DCE-MRI for predicting molecular subtypes of breast cancer
Ming Fan (2018)
10.1186/s13058-019-1187-z
Radiomic signatures with contrast-enhanced magnetic resonance imaging for the assessment of breast cancer receptor status and molecular subtypes: initial results
D. Leithner (2019)
10.1016/J.EJRAD.2019.02.018
Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.
G. DiLorenzo (2019)
10.1186/s13058-018-1039-2
Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer
J. Wu (2018)
10.1002/jmri.26878
Artificial intelligence in the interpretation of breast cancer on MRI
D. Sheth (2019)
10.1007/s10334-020-00892-y
A radiomics pipeline dedicated to Breast MRI: validation on a multi-scanner phantom study
Marie-Judith Saint Martin (2020)
10.1007/s00432-018-2595-7
A study of association of Oncotype DX recurrence score with DCE-MRI characteristics using multivariate machine learning models
Ashirbani Saha (2018)
10.1117/12.2295471
Breast cancer molecular subtype classification using deep features: preliminary results
Z. Zhu (2018)
10.1007/s11517-020-02232-7
A comprehensive hierarchical classification based on multi-features of breast DCE-MRI for cancer diagnosis
H. Liu (2020)
10.1002/jmri.26556
Role of texture analysis in breast MRI as a cancer biomarker: A review
Rhea D Chitalia (2019)
10.1016/j.compbiomed.2019.04.018
Deep Learning for identifying radiogenomic associations in breast cancer
Z. Zhu (2019)
10.1186/s12885-020-07053-3
Diagnosis of triple negative breast cancer based on radiomics signatures extracted from preoperative contrast-enhanced chest computed tomography
Q. Feng (2020)
10.35711/aimi.v1.i1.6
Breast dynamic contrast-enhanced-magnetic resonance imaging and radiomics: State of art
Alessia Angela Maria Orlando (2020)
10.1093/jrr/rrx102
Radiomics and radiogenomics for precision radiotherapy
J. Wu (2018)
10.1016/j.acra.2019.09.012
Breast Cancer Radiogenomics: Current Status and Future Directions.
L. Grimm (2020)
10.1002/jmri.26852
Machine learning in breast MRI
B. Reig (2019)
10.1109/JPROC.2019.2950187
Comparison of Breast MRI Tumor Classification Using Human-Engineered Radiomics, Transfer Learning From Deep Convolutional Neural Networks, and Fusion Method
H. M. Whitney (2020)
10.1155/2019/6978650
Molecular Subtypes Recognition of Breast Cancer in Dynamic Contrast-Enhanced Breast Magnetic Resonance Imaging Phenotypes from Radiomics Data
Wei Li (2019)
10.1016/j.clinimag.2018.08.011
MR imaging features and tumor biomarkers of screen-detected and non-screen detected breast cancers: preliminary results of a comparative study.
E. Panourgias (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar